171 related articles for article (PubMed ID: 16804392)
21. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.
Krausz S; Boumans MJ; Gerlag DM; Lufkin J; van Kuijk AW; Bakker A; de Boer M; Lodde BM; Reedquist KA; Jacobson EW; O'Meara M; Tak PP
Arthritis Rheum; 2012 Jun; 64(6):1750-5. PubMed ID: 22170479
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668
[TBL] [Abstract][Full Text] [Related]
23. Trichuris suis therapy in Crohn's disease.
Summers RW; Elliott DE; Urban JF; Thompson R; Weinstock JV
Gut; 2005 Jan; 54(1):87-90. PubMed ID: 15591509
[TBL] [Abstract][Full Text] [Related]
24. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease.
Hommes D; van den Blink B; Plasse T; Bartelsman J; Xu C; Macpherson B; Tytgat G; Peppelenbosch M; Van Deventer S
Gastroenterology; 2002 Jan; 122(1):7-14. PubMed ID: 11781274
[TBL] [Abstract][Full Text] [Related]
26. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial.
Smith JP; Bingaman SI; Ruggiero F; Mauger DT; Mukherjee A; McGovern CO; Zagon IS
Dig Dis Sci; 2011 Jul; 56(7):2088-97. PubMed ID: 21380937
[TBL] [Abstract][Full Text] [Related]
27. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
Keshav S; Vaňásek T; Niv Y; Petryka R; Howaldt S; Bafutto M; Rácz I; Hetzel D; Nielsen OH; Vermeire S; Reinisch W; Karlén P; Schreiber S; Schall TJ; Bekker P;
PLoS One; 2013; 8(3):e60094. PubMed ID: 23527300
[TBL] [Abstract][Full Text] [Related]
28. Sargramostim for active Crohn's disease.
Korzenik JR; Dieckgraefe BK; Valentine JF; Hausman DF; Gilbert MJ;
N Engl J Med; 2005 May; 352(21):2193-201. PubMed ID: 15917384
[TBL] [Abstract][Full Text] [Related]
29. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.
Lichtenstein GR; Yan S; Bala M; Hanauer S
Am J Gastroenterol; 2004 Jan; 99(1):91-6. PubMed ID: 14687148
[TBL] [Abstract][Full Text] [Related]
30. Anti-interleukin-12 antibody for active Crohn's disease.
Mannon PJ; Fuss IJ; Mayer L; Elson CO; Sandborn WJ; Present D; Dolin B; Goodman N; Groden C; Hornung RL; Quezado M; Yang Z; Neurath MF; Salfeld J; Veldman GM; Schwertschlag U; Strober W;
N Engl J Med; 2004 Nov; 351(20):2069-79. PubMed ID: 15537905
[TBL] [Abstract][Full Text] [Related]
31. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
Wada Y; Cardinale I; Khatcherian A; Chu J; Kantor AB; Gottlieb AB; Tatsuta N; Jacobson E; Barsoum J; Krueger JG
PLoS One; 2012; 7(4):e35069. PubMed ID: 22493730
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
Schreiber S; Fedorak RN; Nielsen OH; Wild G; Williams CN; Nikolaus S; Jacyna M; Lashner BA; Gangl A; Rutgeerts P; Isaacs K; van Deventer SJ; Koningsberger JC; Cohard M; LeBeaut A; Hanauer SB
Gastroenterology; 2000 Dec; 119(6):1461-72. PubMed ID: 11113067
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
34. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Sandborn WJ; Feagan BG; Fedorak RN; Scherl E; Fleisher MR; Katz S; Johanns J; Blank M; Rutgeerts P;
Gastroenterology; 2008 Oct; 135(4):1130-41. PubMed ID: 18706417
[TBL] [Abstract][Full Text] [Related]
35. Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.
Israeli E; Zigmond E; Lalazar G; Klein A; Hemed N; Goldin E; Ilan Y
World J Gastroenterol; 2015 May; 21(18):5685-94. PubMed ID: 25987796
[TBL] [Abstract][Full Text] [Related]
36. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
Dignass A; Stoynov S; Dorofeyev AE; Grigorieva GA; Tomsová E; Altorjay I; Tuculanu D; Bunganič I; Pokrotnieks J; Kupčinskas L; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2014 Sep; 8(9):970-80. PubMed ID: 24534142
[TBL] [Abstract][Full Text] [Related]
37. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.
Sands BE; Chen J; Feagan BG; Penney M; Rees WA; Danese S; Higgins PDR; Newbold P; Faggioni R; Patra K; Li J; Klekotka P; Morehouse C; Pulkstenis E; Drappa J; van der Merwe R; Gasser RA
Gastroenterology; 2017 Jul; 153(1):77-86.e6. PubMed ID: 28390867
[TBL] [Abstract][Full Text] [Related]
39. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.
Israeli E; Goldin E; Fishman S; Konikoff F; Lavy A; Chowers Y; Melzer E; Lahat A; Mahamid M; Shirin H; Nussinson E; Segol O; Ya'acov AB; Shabbat Y; Ilan Y
Clin Exp Immunol; 2015 Aug; 181(2):362-72. PubMed ID: 25846055
[TBL] [Abstract][Full Text] [Related]
40. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
van der Woude CJ; Stokkers P; van Bodegraven AA; Van Assche G; Hebzda Z; Paradowski L; D'Haens G; Ghosh S; Feagan B; Rutgeerts P; Dijkstra G; de Jong DJ; Oldenburg B; Farhan M; Richard T; Dean Y; Hommes DW;
Inflamm Bowel Dis; 2010 Oct; 16(10):1708-16. PubMed ID: 20848453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
